4-chloro-5-[4-(2,5-dichloro-benzyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid | 1192171-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-chloro-5-[4-(2,5-dichloro-benzyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid
• 英文别名: 4-Chloro-5-[4-[(2,5-dichlorophenyl)methyl]piperazin-1-yl]-1-benzofuran-2-carboxylic acid
• CAS: 1192171-25-7
• 化学式: C₂₀H₁₇Cl₃N₂O₃
• 分子量: 439.726
• InChiKey: YNXJWTWDJCIIPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
  申请人：Merck Sante

  公开号：EP2110374A1

  公开（公告）日：2009-10-21

  The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及式(I)的化合物，其中取代基如权利要求中定义的那样，包括其药物组合物及其用于治疗和/或预防及/或改善与FXR活性相关的疾病或障碍的一个或多个症状。本发明还涉及中间体以及化合物式(I)的制备方法。
• BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS
  申请人：Roche Didier

  公开号：US20110105475A1

  公开（公告）日：2011-05-05

  The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及公式（I）化合物，其中取代基如权利要求中所定义，包括其药物组合物以及用于治疗和/或预防和/或改善与FXR活性相关的一种或多种疾病或障碍的症状的用途。本发明还涉及中间体以及制备公式（I）化合物的方法。
• A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3711762A1

  公开（公告）日：2020-09-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

  本发明涉及治疗乙型肝炎病毒感染的方法和药物组合物。特别是，本发明涉及法尼类固醇 X 受体（FXR）激动剂，用于治疗有需要的受试者的乙型肝炎病毒感染的方法。
• Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE)

  公开号：US10071108B2

  公开（公告）日：2018-09-11

  The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

  本发明涉及治疗乙型肝炎病毒感染的方法和药物组合物。特别是，本发明涉及法尼类固醇 X 受体（FXR）激动剂，用于治疗有需要的受试者的乙型肝炎病毒感染的方法。
• BENZOFURANE DERIVATIVES AS FXR MODULATORS
  申请人：Merck Patent GmbH

  公开号：EP2262785B1

  公开（公告）日：2015-01-14